# A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use

> **NCT03145857** · PHASE1,PHASE2 · RECRUITING · sponsor: **AHS Cancer Control Alberta** · enrollment: 1534 (estimated)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DRUG:** [68]Ga-HA-DOTATATE

## Key facts

- **NCT ID:** NCT03145857
- **Lead sponsor:** AHS Cancer Control Alberta
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-03-05
- **Primary completion:** 2040-08
- **Final completion:** 2046-08
- **Target enrollment:** 1534 (ESTIMATED)
- **Last updated:** 2025-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03145857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03145857, "A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03145857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*